Degenerative Disc Disease Articles & Analysis
24 news found
This highly-advanced technology provides successful treatment for patients suffering from chronic low back pain, sciatica, and other debilitating symptoms caused by various issues such as herniated or bulging discs. It has already helped hundreds of thousands of patients avoid spinal surgery, and is currently used in more than 1,000 hospitals and clinics worldwide. Excite ...
This highly-advanced technology provides a highly successful treatment for patients suffering from chronic low back pain, sciatica and other debilitating symptoms caused by herniated discs, bulging discs and more. It has already helped hundreds of thousands of patients avoid spine surgery and is currently used in more than 1,000 hospitals and clinics worldwide. ...
Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). The FDA’s Breakthrough Device designation is designed to expedite the development and review of medical devices that are intended to treat serious or life-threatening ...
Michael Kjær Jacobsen, at the Center for Spine Surgery and Research in Southern Denmark, led the double-blind, prospective, randomized study in more than 100 patients (60 years or older). Participants suffered from degenerative spondylolisthesis and underwent decompression and non-instrumented posterolateral fusion surgery, randomized to either i-FACTOR bone graft or fresh ...
” Excite Medical’s DRX9000 disc treatment, spinal decompression machine is the most advanced in its field. It provides a highly successful treatment for patients suffering from chronic low back pain, sciatica and other debilitating symptoms caused by herniated discs, bulging discs and more. It is a non-surgical procedure and does ...
Excite Medical hopes to create a bigger platform for themselves as a company in its field in effort to provide a healthier and non-surgical alternative approach for patients suffering from chronic back and neck pain and symptoms associated with herniated discs, bulging or protruding inter-vertebral discs, degenerative disc ...
Creative Medical Technology intends to use the net proceeds received from the offering for (i) a clinical study intended to support the safety and efficacy of its StemSpine® Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease, (ii) continued development of its ImmCelzTM immunotherapy platform for the treatment of ...
” Excite Medical’s DRX9000 machine can help people with degenerative disc disease, herniated discs, and bulging discs get safe treatment for their spines and avoid back surgery. ...
Salt Lake City, UT – February 25, 2022 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 clinical trial ...
Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study, to evaluate the safety and efficacy of P-15L Bone Graft for use in transforaminal lumbar interbody fusion (TLIF) surgery in patients with degenerative disc disease (DDD). Results from the study are intended to be used in a Premarket Approval (PMA) submission to the ...
The company’s lead product in development is called LDGraft, and is a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease. In September 2020, Locate Bio in-licensed multiple late-stage orthobiologics assets from the Royal College of Surgeons in Ireland’s (RCSI) University of Medicine and Health ...
The drug-device combination product is based on small peptide (P-15) technology that accelerates new bone formation in patients with degenerative disc disease. It is in a new category of bone graft technology and is one of only two drug-device combination products approved by the U.S. ...
The Westminster, CO-based company also recently received a FDA breakthrough device designation for its P-15L bone graft for the treatment of degenerative disc disease. CardioFocus Marlborough, MA-based CardioFocus has developed the HeartLight X3 endoscopic ablation system for the treatment of drug refractory recurrent symptomatic paroxysmal ...
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy for lumbar ...
The FDA Breakthrough Device Program is designed to accelerate patient access to promising technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Osteochondral lesions are a tear or fracture that involves damage to both the cartilage and underlying bone. ...
The FDA Breakthrough Device Program is intended to help patients receive more timely access to certain technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Osteomyelitis is a progressive, inflammatory infection of the bone, usually caused by bacteria and is estimated to ...
Locate Bio’s lead asset in development, is a low dose, controlled release rhBMP-2 spinal fusion product intended for the treatment of lower back pain caused by degenerative disc disease. Locate Bio is a spin-out from the University of Nottingham and based on the research of Professor Kevin Shakesheff, a world-leading expert in regenerative ...
Excite Medical hopes to expand its business in the middle east and reach more medical facilities to provide the most advance alternative to surgery for herniated discs, bulging discs and degenerative disc disease. About Excite Medical Excite Medical has been long recognized worldwide for its cutting edge ...
At DiscGenics, we are actively monitoring developments in the ongoing coronavirus (COVID-19) pandemic and recommendations from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Utah Department of Health. As the situation continues to rapidly evolve, our top priority remains the health, safety and well-being of our employees and patients, ...
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Phase 1/2 first-in-human U.S. clinical study of IDCT, an allogeneic, injectable Discogenic Cell ...